Gelonghui March 14 丨 Haohai Biotech (688366.SH) disclosed an investor relations activity record sheet showing that the company's fourth-generation organic crosslinked hyaluronic acid products have completed domestic clinical trials and are currently in the late stages of registration review.
The company's medical and aesthetic product pipeline is, on the one hand, filled with hyaluronic acid. On the other hand, the company is also actively exploring the clinical application of various product combinations. At the same time, the company also has a layout in the water light category and botulinum toxin products.
Furthermore, the company made a key layout in medical and aesthetic energy source equipment through the acquisition of European Huamecco.
In the medical and aesthetic field, the company has now formed a business matrix covering the four major categories of hyaluronic acid, genetically engineered preparations for epidermal repair, radiofrequency and laser equipment, and can meet the comprehensive medical and aesthetic consumption needs of end customers for the epidermis, dermis, and subcutaneous tissue through a multi-level business layout.